For more common variants of polymorphisms in the VDR gene, available data indicated their capacity to change disease-specific survival in patients with breast cancer [48], lung cancer [49, 50] ovarian cancer [51] colorectal cancer [52, 53], renal cell carcinoma [54], prostate tumor [55–57], head and neck squamous cell carcinoma [58, 59], glioma [60] and, only very recently, in patients with malignant melanoma [46]. This evidence concerns the gene VDR and melanoma.